Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Novel DehydraTECH(TM) Technology to Address Unmet Antihypertension Drug Market
- Research has shown that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness
- The antihypertension drug market is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents
- Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031
- Lexaria’s patented DehydraTECH(TM) technology offers higher bioavailability of active pharmaceutical ingredients due to, in part, bypassing first-pass-liver processing, improving the speed of onset, and brain absorption
The American Heart Association (“AMA”) refers to high blood pressure, or hypertension, as a “silent killer.” Nearly half of American adults have hypertension but do not know it because there are no obvious symptoms correlating to the condition. However, research finds that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness.
A recent study conducted by the AMA has found that hypertension may be linked to significant bone loss. The bone quality in younger mice with hypertension was similar to the bones of older mice without hypertension present. The study suggests that the effects of hypertension on the bones may mimic aging – making early detection and treatment a necessity to deter excessive bone loss as people age (https://nnw.fm/LiwtD ).
Additionally, a study published by the National Library of Medicine concluded that individuals with mental illnesses had increased blood pressure variability (“BPV”), regardless of age. Since mental illness contributes to the deterioration of autonomic functions, early therapeutic interventions for mental illness may prevent diseases associated with autonomic dysregulation and reduce the likelihood of negative cardiac outcomes (https://nnw.fm/dnXvs ).
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery, has developed a patented technology, DehydraTECH(TM), that has been proven useful for potentially treating hypertension. DehydraTECH improves the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, improving the speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”). The company began developing this technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree.
Lexaria operates four subsidiaries to focus on its different commercial opportunities in their respective industries: Lexaria Pharmaceutical Corp., which investigates new products for hypertension, anti-viral treatments, epilepsy and other drug classes; Lexaria Nicotine LLC (16.67% owned by Altria Ventures Inc.), which investigates oral non-combusted tobacco-derived nicotine product formats; Lexaria Hemp Corp., which pursues business-to-business opportunities with cannabinoids such as cannabidiol (“CBD”) from hemp; and Lexaria Canpharm ULC., which operates a state-of-the-art Health Canada licensed laboratory capable of developing novel psychotropic cannabinoid formulations for potential commercialization in the sectors where it is federally legal to do so.
Lexaria also licenses its DehydraTECH(TM) technology for delivering fat-soluble active molecules and drugs. The company has over 50 pending patents worldwide and 27 granted patents.
The market for antihypertension drugs is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents. Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031. There is a serious unmet need in the antihypertension medication market, which includes a shortage of viable products. Lexaria is leveraging its position and DehydraTECH technology to meet the unmet needs in the market and the demand for new approaches to lower blood pressure.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Research has shown that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness
- The antihypertension drug market is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents
- Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031
- Lexaria’s patented DehydraTECH(TM) technology offers higher bioavailability of active pharmaceutical ingredients due to, in part, bypassing first-pass-liver processing, improving the speed of onset, and brain absorption
The American Heart Association (“AMA”) refers to high blood pressure, or hypertension, as a “silent killer.” Nearly half of American adults have hypertension but do not know it because there are no obvious symptoms correlating to the condition. However, research finds that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness.
A recent study conducted by the AMA has found that hypertension may be linked to significant bone loss. The bone quality in younger mice with hypertension was similar to the bones of older mice without hypertension present. The study suggests that the effects of hypertension on the bones may mimic aging – making early detection and treatment a necessity to deter excessive bone loss as people age (https://nnw.fm/LiwtD ).
Additionally, a study published by the National Library of Medicine concluded that individuals with mental illnesses had increased blood pressure variability (“BPV”), regardless of age. Since mental illness contributes to the deterioration of autonomic functions, early therapeutic interventions for mental illness may prevent diseases associated with autonomic dysregulation and reduce the likelihood of negative cardiac outcomes (https://nnw.fm/dnXvs ).
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery, has developed a patented technology, DehydraTECH(TM), that has been proven useful for potentially treating hypertension. DehydraTECH improves the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, improving the speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”). The company began developing this technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree.
Lexaria operates four subsidiaries to focus on its different commercial opportunities in their respective industries: Lexaria Pharmaceutical Corp., which investigates new products for hypertension, anti-viral treatments, epilepsy and other drug classes; Lexaria Nicotine LLC (16.67% owned by Altria Ventures Inc.), which investigates oral non-combusted tobacco-derived nicotine product formats; Lexaria Hemp Corp., which pursues business-to-business opportunities with cannabinoids such as cannabidiol (“CBD”) from hemp; and Lexaria Canpharm ULC., which operates a state-of-the-art Health Canada licensed laboratory capable of developing novel psychotropic cannabinoid formulations for potential commercialization in the sectors where it is federally legal to do so.
Lexaria also licenses its DehydraTECH(TM) technology for delivering fat-soluble active molecules and drugs. The company has over 50 pending patents worldwide and 27 granted patents.
The market for antihypertension drugs is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents. Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031. There is a serious unmet need in the antihypertension medication market, which includes a shortage of viable products. Lexaria is leveraging its position and DehydraTECH technology to meet the unmet needs in the market and the demand for new approaches to lower blood pressure.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
